Transcode Therapeutics, Inc. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
TransCode reported updated Phase 1a data for TTX-MC138 (anti-miR-10b) as of September 1, 2026: 10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease; three patients remained progression-free at 12 months; disease control extended through six months in 35.7% of patients; no dose-limiting toxicities reported across all doses including 4.8 mg/kg; exploratory biomarker analysis showed treatment-associated antitumor immune activation. The study met its primary safety endpoint.
Why this rating
Early-stage oncology data with durable clinical signals in heavily pretreated population is materially positive for $6.5M-cap biotech; validates lead program justifying further development investment, though Phase 1a remains early-stage with small N and requires Phase 2 confirmation.
Tradability signal
SHORT
conviction 21/100 · expected -0.59% over 4 hrs
SHORT (fade the pop): stock already ran +7.0% on this news, and positive calls in this cell have historically given the pop back (-0.70% over 4 hrs, n=130). Reversion play, lower conviction by design. Exit plan: HARD stop 5% against entry — default width (volatility unmeasured), fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.58 ▼ 6.51% | at our read · unknown $1.69 | +10 min · unknown $1.76 ▲ 4.14% | +30 min · unknown $1.70 ▲ 0.30% | +1 hr · unknown $1.68 ▼ 0.59% | +4 hrs · unknown $1.66 ▼ 1.78% |
The stock had already moved +6.96% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.